ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, vol.25, no.2, pp.219-226, 2016 (SCI-Expanded)
Background. Adalimumab (ADA) is a potent inhibitor of tumor necrosis factor (TNF-alpha). ADA treatment suppresses proinflammatory cytokines, leading to a decrease or inhibition of the inflammatory process.